TICKERNERD
Menu
ACHVACHVHealthcare · Biotechnology

ACHV Stock Forecast: Achieve Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.06
−3.02% on the day

The 11 Wall Street analysts covering Achieve Life Sciences, Inc. hold a median 12-month price target of $13 — +77.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$726.5M
Ticker Nerd rank
28 / 100
Median analyst target
$13
Analysts covering
11
Revenue$0.0
Operating income−$18.4M
Net income−$74.8M
Free cash flow−$11.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.0%
1M
+4.3%
YTD
+42.1%
1Y
+123.4%
From 52W high
−17.2%
From 52W low
+166.4%
$2.65
$8.53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACHV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Achieve Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Accruals
82
Size
49
Growth
44
Value
41
Revisions
28
Volatility
18
Quality
13
Issuance
12

Momentum (93): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACHV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACHV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26ACHVHigh $21Median $13Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $9Median $13High $21

The green dot is the last close — the median target sits +77.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Morgan StanleyInitiatesOverweight$13
22 June 2026HC Wainwright & Co.ReiteratesBuy$12
22 June 2026HC Wainwright & Co.ReiteratesBuy—
21 Apr 2026Canaccord GenuityInitiatesBuy—
16 Apr 2026HC Wainwright & Co.ReiteratesBuy—
25 Mar 2026HC Wainwright & Co.ReiteratesBuy—
25 Nov 2025CitizensInitiatesMarket Outperform—
21 Aug 2025HC Wainwright & Co.InitiatesBuy—
14 Nov 2024Rodman & RenshawInitiatesBuy—
27 Sept 2024Raymond JamesInitiatesStrong Buy$20
15 Aug 2024OppenheimerReiteratesOutperform—
13 May 2024OppenheimerMaintainsOutperform—
17 Apr 2024JonesTradingInitiatesBuy—
1 Apr 2024OppenheimerReiteratesOutperform—
5 Mar 2024Lake StreetMaintainsBuy—
12 Dec 2023OppenheimerMaintainsOutperform—
1 June 2023Lake StreetMaintainsBuy—
31 May 2023Lake StreetMaintainsBuy—
10 May 2023Lake StreetMaintainsBuy—
17 Mar 2023OppenheimerReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACHV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACHV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Achieve Life Sciences, Inc. returned +123.4% against +17.5% for the S&P 500, dividends included.

ACHV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26ACHVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACHV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Achieve Life Sciences, Inc. (ACHV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.6×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
−45.0×

Cheaper than 99% of US stocks

EV / EBITDA
−9.5×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−845.0%

Higher than 2% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Achieve Life Sciences, Inc. (ACHV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Achieve Life Sciences, Inc. has a market value of $726.5M and an enterprise value of $554.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$114.0M.

  • Diluted earnings per share, trailing twelve months: $−1.55.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 102.7M.

  • Trailing P/E: −5.6×; forward P/E: −11.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Achieve Life Sciences, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ACHV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACHVAchieve Life Sciences, Inc.$726.5M
28
AURAAura Biosciences, Inc.$723.2M
39
FDMT4D Molecular Therapeutics, Inc.$727.6M
52
CBIOCrescent Biopharma, Inc.$717.4M
54
MNPRMonopar Therapeutics, Inc.$736.8M
57
CTMXCytomX Therapeutics, Inc.$711.2M
47
ZVRAZevra Therapeutics, Inc.$705.1M
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Achieve Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACHV news & analysis

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

GlobeNewsWire · 3 Sept 2026neutral

Achieve Life Sciences announced that its board of directors approved stock option grants to purchase an aggregate of 315,000 shares and restricted stock unit awards covering 283,000 shares for seven new employees under its 2024 Equity Inducement Plan.

Why it matters — This indicates the company's ongoing hiring and equity-based employee retention efforts as it advances development of cytisinicline.

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

GlobeNewsWire · 3 Aug 2026positive

Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President of CMC and Supply Chain, and Gloria Cosgrove as Senior Vice President of Quality, both bringing decades of pharmaceutical leadership experience.

Why it matters — Strengthening CMC, supply chain, and quality leadership signals that Achieve is building the operational infrastructure needed to support the potential commercialization of cytisinicline.

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

GlobeNewsWire · 31 July 2026neutral

Achieve Life Sciences announced that its board of directors approved stock option grants for 1,190,000 shares and restricted stock unit awards for 125,000 shares to six new employees under the company's 2024 Equity Inducement Plan.

Why it matters — The inducement awards signal the company is hiring and incentivizing new talent, which may be relevant as it progresses development of cytisinicline for nicotine dependence.

FAQ

Frequently asked questions about ACHV stock

What is the ACHV stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Achieve Life Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACHV stock a buy right now?

Of the 11 analysts covering Achieve Life Sciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Achieve Life Sciences, Inc. 28 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACHV?

As at 11 Sept 2026, Achieve Life Sciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will ACHV stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +77.1% from the last close, and Ticker Nerd's factor model ranks Achieve Life Sciences, Inc. 28 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACHV stock forecast for 2030?

No analyst covering Achieve Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACHV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has ACHV stock performed over the past year?

Achieve Life Sciences, Inc. returned +123.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Achieve Life Sciences, Inc. do?

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline, a treatment designed to address nicotine dependence and support smoking cessation.

What is the latest news on ACHV?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Achieve Life Sciences Announced Granting of New Hire Inducement Awards". Achieve Life Sciences announced that its board of directors approved stock option grants to purchase an aggregate of 315,000 shares and restricted stock unit awards covering 283,000 shares for seven new employees under its 2024 Equity Inducement Plan.

Company

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing cytisinicline, a treatment designed to address nicotine dependence and support smoking cessation. Its core work centers on advancing this non-opioid, plant-derived therapy for adults seeking help with nicotine withdrawal and tobacco use disorder. The company operates in the healthcare and biotechnology sectors, where it contributes to efforts aimed at expanding pharmacological options for addiction treatment. Achieve Life Sciences’ current business is centered on cytisinicline across key markets in North America and the United Kingdom, reflecting its focus on regulated prescription therapies for nicotine addiction. Headquartered in Bothell, Washington, with operations also connected to Vancouver, British Columbia, the company remains dedicated to a single therapeutic area and a narrowly defined pharmaceutical portfolio.

CEO Dr. Andrew D. Goldberg M.D. · 28 employees · United States · https://www.achievelifesciences.com